As the earnings season kicks off for the biotechnology sector, William Blair analyst John Sonnier outlined updated earnings per share (EPS) estimates for Gilead …
As he previews fourth-quarter results for these two biotech giants, William Blair analyst John Sonnier is setting positive expectations on Gilead Sciences, Inc. (NASDAQ:GILD) …
Last Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase III POLARIS topline data with sofosbuvir (nucleotide polymerase inhibitor)/velpatasvir (NS5A inhibitor)/voxilaprevir (protease inhibitor) in treatment-naïve …
The biotech world is experiencing volatility in the midst of a drug development discontinuation for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) and word from the FDA to …
William Blair analyst John Sonnier is out with a research report on Exelixis, Inc. (NASDAQ:EXEL) as the biotech company’s shares have been shooting …
Friday morning before market open, Bristol-Myers Squibb Co (NYSE:BMY) came to terms with the failure of its Phase III CheckMate-026 trial evaluating Opdivo …
William Blair’s healthcare analyst John Sonnier weighed in with a favorable report on Gilead Sciences, Inc. (NASDAQ:GILD), after the company announced positive clinical data featuring the company’s next-generation, …
William Blair’s healthcare analyst John Sonnier weighed in with a few insights on Agenus Inc (NASDAQ:AGEN), as the company yesterday announced a transaction with an investor group …
In light of the recent market volatility last week, William Blair issued a note to investors on August 27 highlighting the firm’s top …
William Blair’s healthcare analyst John Sonnier weighed in today with a few insights on Exelixis, Inc. (NASDAQ:EXEL), after the biopharmaceutical company announced that the the Swiss authority which …